CytoSolve offers a revolutionary and proven information-centric platform that enables accurate quantitative mechanistic models, for predicting complex molecular phenomena, for the rapid testing and development of single and multi-combination compounds for drug, nutritional supplement, and medical foods, by minimizing the need for in vitro and in vivo testing.
Integrating Published Scientific Research from Global Institutions
RESEARCH UPDATE: 31 AUGUST 2015
Reviewed 214,569 experiments across 4,627 institutions by 11,831 scientists.
Backbone for Basic Research
Major institutions and foundations such as the University of Southern California, Rodale Institute, Guthy-Jackson Foundation have contracted with CytoSolve for molecular systems understanding of Alzheimer’s, Genetically Modified Organisms, and Neuro-Myelitis Optica.
Development of Nutritional Products
CytoSolve has developed over twenty of its own proprietary nutritional products which are being formulated and a phased launch in 2015 direct to consumers and through major retailers.
Supplements Testing and Certification
The United States Pharmacopeia (USP) appointed Dr. Ayyadurai on the Dietary Supplements Expert Committee. CytoSolve was engaged by the USP for predicting toxicity of multi-combination supplements in a major project for the US Army. CytoSolve has recently built a significant pipeline of hundreds of nutritional products and foods companies, and stakeholders including Whole Foods, who will be engaging CytoSolve for testing and validation of nutritional and food products for humans and pets.
CytoSolve has created a multi-combination drug for pancreatic cancer, which has received FDA allowance with exemption to proceed to clinical trials, that has resulted in the development of a new JV with MD Anderson Cancer Center. In addition, Alnylam Pharmaceuticals, a leading provider of sRNAi therapeutics has recently contracted with CytoSolve for the modeling of Hereditary AngioEdema (HAE), towards the development of multi-combination therapeutics.